Privacy voorkeur

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


ESMO 2017 in-depth: IFCT-0302 trial

This year the ESMO congress took place in Madrid from 8 - 12 September. Prof. Virginie Westeel, head of the Thoracic Oncology unit in the University Hospital of Besançon, explains the design and results of the IFCT-0302 trial. This randomised trial compared two follow-up protocols for patients with completely resected non-small cell lung cancer.

  • This program is editorially independent and is financially made possible by

Related items

Congress news

ESMO 2017 in-depth: Neoadjuvant chemotherapy in cervical cancer

This year the ESMO congress took place in Madrid from 8 - 12 September. Sudeep Gupta, Professor of Medical Oncology at Tata Memorial Hospital in Mumbai, explains the design and results of his trial, that examined whether neoadjuvant chemotherapy followed by surgical removal of the tumour could improve outcomes in patients with locally advanced cervical cancer compared to standard treatment with chemoradiation.

Congress news

ESMO 2017 in-depth: TONIC trial

This year the ESMO congress took place in Madrid from 8 - 12 September. Marleen Kok, MD, PhD at The Netherlands Cancer Institute in Amsterdam, explains the design and first results of the TONIC trial. This adaptive phase II trial evaluated the response rate to nivolumab after induction treatment in patients with triple-negative breast cancer.

Congress news

ESMO 2017 in-depth: KEYNOTE-040 trial

This year the ESMO congress took place in Madrid from 8 - 12 September. E. This phase III trial evaluated the efficacy of checkpoint inhibitor pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma after platinum-based chemotherapy.

Congress news

ESMO 2017 in-depth: RANGE trial

This year the ESMO congress took place in Madrid from 8 - 12 September. Daniel Petrylak, Professor of Medicine and Urology at Yale School of Medicine, explains the design and results of the RANGE trial. This phase III randomised trial evaluated the efficacy of ramucirumab in combination with docetaxel in patients with advanced urothelial cancer who failed prior platinum-based therapy.